July 24, 2012

Molecular Diagnostics and Companion Therapies: Partnerships, Payment and Evidence Development

Co-Sponsored by the National Pharmaceutical Council

The promise of molecular diagnostics centers on its ability to use the genetic markers of individual patients to tailor more effective treatment plans. This form of personalized medicine can focus therapy on those who are most likely to respond, enhancing effectiveness and reducing treatment costs over a population. But the pathway to development of personalized approaches based on molecular diagnostics is dependent on securing credible evidence of clinical utility, as well as managing the interplay between diagnostic information and decisions about follow-on treatment.

This meeting of the Health Industry Forum will review the expanding role of molecular diagnostics in our healthcare system as well as potential barriers to adoption. It will examine the business models for developing personalized treatments including the increasingly common collaborations between the drug and diagnostic industries. It will also discuss the evidence payers and consumes will require for adoption, and the role of independent clinical review authorities in setting standards for clinical utility.

Agenda

Participants

Presentations

Molecular Diagnostics and their Evolving Influence on the Healthcare System
Harry Glorikian, Founder and Managing Partner, Scientia Advisors

Delivering Value Through Personalized Medicine: An Industry Perspective
Josephine A. Sollano, DrPH, Head, Global HEOR and Medical Communications, Pfizer Oncology

Opportunities and Challenges in the Development of Companion Diagnostics
E. Patrick Groody, PhD, Divisional Vice President, Research and Development, Abbott Molecular

Payer Perspectives on Molecular Diagnostics
Robert W. Dubois, MD, PhD, Chief Scientific Officer, National Pharmaceutical Council

Molecular Diagnostic Testing Challenges
Elaine Jeter, MD, Medical Director, Palmetto GBA

Personalized Medicine: Perspectives on the New Science of Genetic Testing and Molecular Diagnostics
Lewis G. Sandy, MD, Senior Vice President, Clinical Advancement, UnitedHealth Group

Collaborative Development of Evidentiary Standards for Clinical Utility of MDx
Sean Tunis, MD, MSc, Director, Center for Medical Technology Policy

Biomarkers
Joan McClure, MS, Senior Vice President, Clinical Information and Publications, National Comprehensive Cancer Network